Overview
AOD-9604 is a synthetic analog of the C-terminal fragment (residues 176–191) of human growth hormone. It was specifically engineered to retain GH's fat-loss properties while removing its effects on blood sugar and IGF-1 — making it one of the most isolated lipolytic peptides studied.
Mechanism of action
AOD-9604 binds beta-3 adrenergic receptors on adipocytes, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage). Unlike full-length GH, it does not activate the GH receptor, leaving glucose metabolism and IGF-1 signaling untouched.
Reported benefits
- Targeted reduction of stubborn adipose tissue (abdomen, hips)
- No impact on blood glucose or insulin sensitivity
- Does not affect natural GH/IGF-1 axis
- Reported cartilage and joint-supportive effects in animal models
Research dosing
Common research protocols: 300 mcg subcutaneously each morning in a fasted state, 5–6 days per week, for 8–12 week cycles.
Considerations
Effects are gradual and most visible when paired with caloric deficit and consistent training. Side-effect profile in studies has been notably mild compared to other GH-axis peptides.
Research use only. This article is provided for educational purposes and is not medical advice. Products sold on this website are for laboratory research only and are not intended for human consumption. Not evaluated by the FDA.
Continue reading